Patients needed for patent 1, patent 2 and chest clinical trials
PATENT 1, PATENT 2 and CHEST trials are currently underway at the Wesley Pulmonary Hypertension Unit and new patients are required. We are trialing Riociuguat - a direct stimulator of the soluable Guanylate Cyclase which plays a significant role in the nitric oxide pathway and is intended for the treatment of PH. The trial is in association with Bayer and Wesley Research Institute.
In PATENT 1 & 2 trials, the patient can already be on therapy with an endothelin receptor antagonists (bosentan, sitaxentan or ambrisetan) or naïve to PAH therapy.
The CHEST trial is using the same agent for non-operable chronic thromboembolic disease related PAH. (CTEPH)
We are accepting patients now for these trials by referral.
About The Wesley Pulmonary Hypertension Unit
The Wesley Pulmonary Hypertension Unit (WPHU) has established itself as one of the largest specialised treatment centres in Queensland. In just 18 months of operation, the clinic has reviewed patients for treatment and have been actively enrolling patients into international clinical trials. The treatment programs include monotherapy and combination treatments in keeping with the best available therapies for PAH.
All PBS funded medications for monotherapy
Combination therapy – funded or via clinical trials
Clinical Trials with WRI
PATENT 1 and 2 trials
The Wesley Pulmonary Hypertension Unit multidisciplinary team includes:
Dr Andrew Scott
Thoracic and Sleep Physician
P: (07) 3876 8405
F: (07) 3870 3212
Dr David Cross
P: (07) 3858 8600
F: (07) 3870 4917
Helen Woodhouse, CNC
P: 0404 650 281
F: (07) 3871 3222